The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Updates from DESTINY-Gastric 01

Name: Updates from DESTINY-Gastric 01
Uploaded: 2020-07-02T00:00:00Z
Duration: 3 min 2 s
Description: Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, discusses results from DESTINY-Gastric 01 (NCT03329690), a Phase II study investigating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Kensei Yamaguchi • 2 Jul 2020

ESMO WCGIC 2020

Gastric Cancer Gastroesophageal Cancer Gastrointestinal Cancer 5-fluorouracil Antibodies Trastuzumab deruxtecan

DESTINY-Gastric01

Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, discusses results from DESTINY-Gastric 01 (NCT03329690), a Phase II study investigating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).